Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.

Zorica MiloševićJasna BankovićJelena DinićChrisiida TsimplouliEvangelia SeretiMiodrag DragojVerica PaunovićZorka MilovanovićMarija StepanovićNikola TanićKostantinos DimasMilica Pesic

Published in: Cellular oncology (Dordrecht) (2018)

Our data support results from recent phase I clinical trials using combinations of AZD2014 and PTX for the treatment of solid tumors. Such combinations may also be employed for the design of novel targeted ATC treatment strategies.

Keyphrases

clinical trial
cell proliferation
electronic health record
cancer therapy
big data
randomized controlled trial
machine learning
human health
deep learning
chemotherapy induced